SS-31 (Elamipretide)

SS-31 (elamipretide) is a synthetic aromatic-cationic tetrapeptide developed by Hazel Szeto and Peter Schiller at Weill Cornell Medicine, and subsequently advanced clinically by Stealth BioTherapeutics. Its full sequence is D-Arg-2′6′-Dmt-Lys-Phe-NH2, and its development was predicated on a foundational observation: the compound carries a net positive charge that enables it to accumulate selectively in the inner mitochondrial membrane at concentrations hundreds of times greater than systemic levels — a property that distinguishes it from generic antioxidants that operate non-specifically. It belongs to a class sometimes called 'Szeto-Schiller' or SS peptides, a small group of mitochondria-penetrating compounds, and SS-31 is by far the most clinically advanced member of that class.

The proposed mechanism of action centers on cardiolipin, a phospholipid unique to the inner mitochondrial membrane that plays a structural and functional role in organizing the electron transport chain complexes into 'supercomplexes.' Research suggests that under conditions of oxidative stress, aging, or ischemia, cardiolipin becomes oxidized and loses structural integrity, compromising proton gradient efficiency, increasing reactive oxygen species (ROS) production, and triggering apoptotic signaling via cytochrome c release. In vitro and animal model studies indicate that SS-31 binds directly to cardiolipin, stabilizing its association with cytochrome c, reducing electron leak and ROS generation at Complexes I and III, and restoring membrane potential. Importantly, this mechanism is not simple free-radical scavenging — it is structurally targeted, which is why the research community has regarded it with more seriousness than many antioxidant-class compounds.

The evidence base for SS-31 is genuinely more developed than most research peptides, though it stops well short of regulatory approval. In animal models (mouse, rat, canine, primate), published studies have reported improvements in cardiac output following ischemia-reperfusion injury, attenuation of age-related skeletal muscle decline (sarcopenia), improved renal function in models of acute kidney injury, and preservation of auditory function in noise-induced cochlear damage models. In human trials, Stealth BioTherapeutics conducted the MMPOWER-3 trial (n=218, 2019) in patients with primary mitochondrial myopathy — a Phase III RCT that did not meet its primary endpoint of improved exercise tolerance at 24 weeks, representing a notable setback for the clinical development program. However, secondary endpoints and earlier Phase II data suggested improvements in fatigue and patient-reported outcomes. A separate Phase II trial in heart failure with preserved ejection fraction (HFpEF, n=71, 2020) reported improvements in peak oxygen consumption and 6-minute walk distance versus placebo, considered a more encouraging signal. Additional Phase I/II data exist in the context of renal protection during cardiac surgery and in Barth syndrome. It should be stated clearly: none of these trials resulted in approval, and anecdotal self-reported use in the biohacking community remains a small and methodologically weak data source that should be weighted accordingly.

Dosing ranges reported in the published clinical literature — provided here strictly as research context and not as a recommendation for human use — have varied by indication. Intravenous infusions in cardiology trials used doses in the range of 0.05 to 0.25 mg/kg. The MMPOWER program used subcutaneous injections of 40 mg/day. Some earlier Phase I work explored single doses from 0.01 to 1.0 mg/kg IV. In preclinical rodent studies, doses of 1–5 mg/kg subcutaneously were commonly employed. The self-reported biohacker community, where subcutaneous administration is typical, tends to describe doses far lower than those in clinical trials — frequently in the range of 1–10 mg per session — though this falls entirely outside the framework of controlled research and should not be interpreted as validated or safe dosing. Reconstitution in bacteriostatic water is standard for lyophilized powder presentations. Reconstituted solution should be refrigerated and used within standard bacteriostatic water stability windows; lyophilized powder should be stored frozen and protected from light.

SS-31 carries an unusual legal and regulatory profile. It is not approved by the FDA, MHRA, EMA, or TGA for any human indication, and it is not a scheduled or controlled substance in major jurisdictions — placing it technically in the research-chemical-unregulated category in the US and UK. However, its formal clinical development history (IND, multiple registered trials) means it occupies a different category of regulatory scrutiny than compounds that have never entered formal drug development. In the US, sourcing SS-31 as a research chemical from peptide vendors is legal in the narrow sense of not being explicitly prohibited, but the FDA's authority over unapproved drugs used in humans remains relevant. COA verification from any vendor is non-negotiable: given the compound's complexity (a tetrapeptide with non-standard amino acid residues including 2′,6′-dimethyltyrosine), synthesis quality and sequence accuracy should be verified by HPLC purity data (>98% is the appropriate bar) and ideally mass spectrometry confirmation. Vendors who cannot provide both should be considered high-risk. This content is published for educational purposes only and does not constitute medical advice. Peptides described here are research chemicals not approved for human use.